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Oral Cancer Screening for Asymptomatic Adults: Do the United States 
Preventive Services Task Force Draft Guidelines Miss the Proverbial Forest 
for the Trees? 
As experts in the field and regular readers of this journal, we are all acutely 
aware of the sobering statistics on oral cancer: in the United States there are an 
estimated 275,000 men and women alive with a prior diagnosis of oral cavity or 
pharyngeal cancer1. It is estimated that an additional 41,000 cases will be 
diagnosed in 2013 alone, with just under 8,000 individuals dying of their 
disease2. For the period 2003-2009, the estimated 5 year relative survival rate for 
patients diagnosed with oral and pharyngeal cancer is 62% in comparison to the 
general population1. For black men, the results are more discouraging, with a 5 
year relative survival of just under 40%. Looking at lifetime risk, a child born 
today has an estimated 1.1% likelihood of developing oral cavity or pharyngeal 
cancer at some point during their life3. The stage at which the cancer is 
diagnosed has a significant effect on overall survival. Localized disease, 
representing disease confined to the primary site, is associated with an 83% 5-
year survival rate. With spread to the regional lymph nodes, the 5-year survival 
drops to just under 60%. The statistics are even grimmer in the presence of 
distant metastasis, with the 5-year survival dropping to 36%. 
With that backdrop in mind, the United States Preventive Services Task Force 
(USPSTF) recently released a draft Recommendation Statement which 
concluded that for adults age 18 years or older seen in the primary care setting, 
the “current evidence is insufficient to assess the balance of benefits and harms 
of screening for oral cancer in asymptomatic adults. Evidence is lacking, of poor 
quality, or conflicting, and the balance of benefits and harms cannot be 
determined.”  
Rather than representing a paradigm shift, this statement is simply an update of 
the 2004 USPSTF recommendations, which similarly concluded “there was 
insufficient evidence to recommend for or against routine screening for oral 
cancer in adults4.” Other expert groups have reached comparable conclusions. 
For example, the reader is referred to the “Evidence-based clinical 
recommendations regarding screening for oral squamous cell carcinomas5” 
recently published by a panel convened by the American Dental Association 
(ADA) Council on Scientific Affairs, which however takes a more pragmatic 
approach to this question. 
Specifically, the USPSTF was unable to offer a recommendation on the benefits 
versus risks of routine visual oral cancer screening of asymptomatic patients who 
present in the primary care setting. This decision was based on their assessment 
of a lack of evidence in three areas: how well do oral cancer screening exams 
detect disease? Do the harms associated with screening outweigh the potential 
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Rather than arbitrarily denouncing the entirety of these recommendations, the 
authors are to be at least commended for highlighting the risk factors for 
developing oral cancer: smoking, heavy alcohol consumption, betel quid use, and, 
for a subset of oropharyngeal cancers, infection with high risk human 
papillomavirus virus (although I disagree with the suggestion that there is 
sufficient evidence at this point to include infection with candida or bacterial flora 
as oral cancer risk factors). These comments may help to educate both the 
general public as well as those health care providers who may have less 
experience in this area. The guidelines also accurately note that potential 
screening adjuncts, such as toluidine blue, chemiluminescence, 
autofluorescence and brush cytopathology lack sufficient evidence to 
recommend their routine use in the primary care setting. In low risk populations, 
reliance on the results of these screening adjuncts, in the absence of clinical 
correlation, is associated with an unacceptable rate of false positives. Likewise, 
the absence of well-designed studies evaluating the risks and benefits of oral 
cancer screening that are of direct relevance to the population of the United 
States (the target audience of this draft statement) must be acknowledged.  
However, an alternative approach to looking at this question should be 
considered, one that also requires examining this issue from a clinical 
perspective (curiously, there is no indication that the USPSTF sought input from 
clinical specialists in this area; namely oral pathologists, oral surgeons, general 
dentists, public health dentists, etc…). Let me clarify, before being misquoted, 
that I am not implying that biomedical science and clinical care are opposing 
paradigms. We are all acutely aware that, as health care providers, treatment 
decisions must be based on a solid evidence-based foundation backed by 
rigorous scientific investigation. Rather, the approach that should be followed in 
answering this question is one that reconciles the available evidence, or lack 
thereof, with a more clinically applicable approach that takes into account the 
realities of the primary care dental setting. With that in mind, lets review these 
areas:  
1. How well do oral cancer screening exams detect disease (i.e. their
performance characteristics)?  
For the purpose of this discussion, the screening examination should be defined 
as a thorough visual and tactile inspection of the head and neck structures and 
the accessible oral cavity executed by a well-trained general dentist in the 
primary care dental setting, and performed on all patients of record as part of the 
routine patient assessment process6. As needed, this is supplemented by 
biopsies of any areas of suspicion, with the goal being to identify all variations 
from normal, including but not restricted to potentially preneoplastic conditions (I 
prefer this term over the WHO’s terminology of “potentially malignant disorders”) 
and early stage oral cancer.  
As noted in the USPSTF report, the two studies that most approximate these 
characteristics are from the United Kingdom, which has an oral cancer 
prevalence similar to that of the United States. These studies reported 
sensitivities in the low 70s and specificities approaching 100 percent, although 
these also highlighted the dilemma of identifying the gold standard, which in 
these studies was a second examination by a specialist in oral pathology/oral 
medicine. 
Examining this from a more pragmatic perspective, considering that greater than 
90% of intraoral malignancies are represented by squamous cell carcinomas, a 
neoplasm of surface epithelium, a thorough visual and tactile examination by a 
well-trained dentist in the primary care setting, coupled with a reasonable degree 
of suspicion for all white, red or ulcerated lesions of undetermined etiology, 
should permit identification of the vast majority of early oral squamous cell 
carcinomas. Clearly, the accuracy with which dental providers in the primary care 
setting can identify and triage potentially preneoplastic conditions and early stage 
oral cancer is dependent on both their training and clinical experience. 
Consequently, as educators, it is critical that our dental school graduates are 
both proficient and confident in their ability to assess soft tissue lesions. 
Additionally, as suggested in the recent guidelines from the ADA’s Council on 
Scientific Affairs referred to previously, “the clinician can reduce the risk of 
performing unnecessary biopsies by obtaining an opinion by a dental or medical 
care provider who has advanced training and experience in diagnosis of oral 
cancer and its precursor lesions5.” 
More importantly though, these guidelines fail to recognize that it is not realistic 
to separate the oral cancer screening component from the overall comprehensive 
head and neck examination that all primary care dental providers perform on 
their patients.  This intraoral and extraoral examination is arguably the most 
important component of every dental patient’s routine assessment, and includes 
a thorough review not just of the teeth and periodontal supporting structures, but 
of all hard and soft tissues of the visible oral cavity, as well as the cervical area 
and the skin of the face. The purpose of this examination is to identify every 
departure from normal, ranging from the more common tooth-related conditions, 
such as abscessed teeth and periodontal disease, to infectious processes (e.g. 
candidiasis; oral manifestations of HIV infection; deep fungal infections), reactive 
soft tissue lesions (e.g. mucoceles, fibromas), and immune-mediated processes 
(e.g. lichen planus, pemphigoid), to name a few. The diagnosis and management 
of these non-malignant processes is a critical component of the day-to-day 
practice of dentistry,7 and consequently the identification of these conditions 
cannot be arbitrarily separated from the “oral cancer” screening exam. 
2. Do the harms associated with screening outweigh the potential benefits?
The draft version of the USPSTF report states that “none of the studies in our 
review reported on harms from the screening test itself or from false-positive or 
false-negative test results. Screening using visual inspection and palpation 
should be low risk. However, any time devoted to it would reduce opportunity for 
other interventions that might have greater impact on health outcomes.”  
In reality, a thorough head and neck examination by a well-trained and 
competent dentist in the primary care setting requires no special equipment 
(good lighting, a dental mirror and gauze), no additional expense, and at most 2-
3 minutes of the practitioner’s time. Other than the minor potential surgical risks 
associated with a biopsy procedure, where deemed necessary, routine oral 
screening is in no way an invasive, time consuming, or costly procedure, and is 
not associated with any significant degree of potential intraprocedural morbidity 
(e.g. perforation following colonoscopy for the detection of colorectal cancer) or 
long-term sequelae resulting from exposure to ionizing radiation (e.g. 
mammography for the detection of breast cancer).  
It is also worth pointing out that the potential benefits of performing an oral 
cancer screening examination are not simply limited to detecting patients with 
oral cancer or potentially preneoplastic conditions. In addition to the many more 
commonly encountered conditions that are identified by means of the 
examination, this is also an opportunity to start a dialogue between clinician and 
patient on aspects such as modifying risk factors that are associated with an 
increased risk of developing oral cancer. As practitioners, we have all 
experienced the patient who, after undergoing a routine oral cancer examination, 
volunteers that he or she is interested in quitting smoking. There is also evidence 
that patients with potentially preneoplastic conditions of the oral cavity, such as 
idiopathic leukoplakia, may benefit from the elimination of risk factors such as 
smoking8.  
It is also accepted that many potentially preneoplastic conditions of the oral 
cavity, such as verrucous hyperplasia, have an unpredictable natural course, and 
overtreatment could result in adverse consequences for the patient. But rather 
than discount the potential benefits of early detection in these situations, would it 
not be better to instead develop clinically relevant guidelines for the assessment 
and management of patients identified with these conditions that would help 
guide our colleagues in the primary care setting? 
Ultimately however, the balance as to whether the potential benefits of routinely 
screening for oral cancer outweigh the risks depends on the answer to the next 
question:  
3. Does detection of oral cancer through screening reduce morbidity or mortality?
As with other position papers in this area, the USPSTF statement bases much of 
its analysis on the findings from the Trivandrum Oral Cancer Screening Study9, in 
which administrative units in the Trivandrum district, an area of India known to 
have a high risk of oral cancer, were randomized so that residents either 
received three rounds of home-based oral screening at 3-year intervals by non-
medical university graduates with minimal training in oral pathology or were 
assigned to a non-intervention control group. The overall mortality rate from oral 
cancer did not differ between the groups in the screened districts versus those in 
the control districts. However, participants from the intervention group who 
smoked or used alcohol had significantly lower overall mortality rates from oral 
cancer than participants from the unscreened control group. Among subjects who 
did not use tobacco or alcohol, these differences were not significant. While not 
intending to critique the methodology of this study, there are recognized 
differences in study parameters that preclude directly extrapolating from these 
findings to the U.S. situation: the incidence of oral cancer is much higher in the 
geographic area studied than in the U.S., tobacco use in the study area consists 
predominantly of bidi, a locally produced cigarette associated with a potentially 
greater risk of oral cancer development than conventional cigarettes10, minimally 
trained non-health care workers performed the screening examinations, the study 
involved home visits to the study participants with the explicit goal of performing 
an oral cancer examination as opposed to being a limited part of a routine dental 
examination and only 62% of study participants with identified lesions complied 
with referral for follow up treatment. Interestingly though, patients identified with 
oral cancer in the intervention group were more likely to have early stage disease 
(41% versus 23% stage I or II) and higher 5-year survival rate (50% versus 34%) 
compared with the control group. 
This segues nicely to another issue posed by the USPSTF, namely the 
uncertainty regarding how much of the improved survival associated with early 
diagnosis is due to lead time bias (implying that an earlier diagnosis leads to an 
apparent longer survival regardless of whether the earlier access to treatment 
affects the natural history of the disease), or length time bias (the observation 
that because there are subsets of oral cancers that progress at different rates, 
those that progress more rapidly than others, and hence lead to earlier death, are 
less likely to be detected by routine screening; the inference being that those 
cancers that are detected at an earlier stage through screening examinations 
may inherently have less aggressive biologic potential, thereby making it appear 
that early diagnosis leads to improved survival). The USPSTF draft statement 
argues that “harms of treatment for screen-detected oral cancer and its potential 
precursors … may result from complications of surgery, radiotherapy, and 
chemotherapy. The natural history of screen-detected oral cancer is not well 
understood and, as a result, the harms from overdiagnosis and overtreatment are 
not known”.  
There is no doubt, as alluded to above, that tumor growth rates vary, based on 
factors such as the inherent biologic properties of the tumor, host resistance and 
anatomic location. But how does this “limited knowledge” of the natural history of 
screen-detected oral cancer translate to the clinical setting? As a clinician, upon 
diagnosing an early stage cancer in an otherwise healthy patient, would you ever 
consider advising your patient that the benefits of undergoing treatment are 
unknown, since “the natural history of screen-detected oral cancer is not well 
understood and … the harms from … overtreatment are not known”? 
The implication that we should not perform routine screenings in the primary care 
setting is clearly not in our patients’ best interests. Not attempting to identify 
cancerous lesions at their earliest stage, particularly when this can be 
accomplished by means of a simple non-invasive examination while the patient is 
already sitting in the dental chair, could be viewed as paternalistic. While there 
clearly can be indications for not proceeding with treatment for a small subset of 
patients diagnosed with oral cancer through screening, e.g. due to poor overall 
health status, even in these cases, this decision should only be made following a 
dialogue that recognizes the patient’s wishes, the likelihood of a favorable 
outcome and the recommendations of the treatment team (i.e. informed consent). 
Ultimately, in order for the patient to make an informed decision, does the cancer 
not have to first be identified? 
In summary, several questions come to mind after reading these guidelines. Why 
the arbitrary attempt to separate the “oral cancer screening” from the overall 
head and neck examination?  What guidance, if any, do these recommendations 
offer to the patient or the practicing clinician? Do the inevitable news headlines 
suggesting that there is no clear benefit to screening for oral cancer send the 
right message at this point in time, considering the progress that has been made 
in reducing the death rate from oral cancer over the past several decades? Does 
the emphasis on the absolute need for suitably powered randomized controlled 
trials conclusively supporting the benefit of routine oral cancer screening in the 
primary care setting ultimately benefit our patients? By not performing a routine 
oral cancer examination as part of a comprehensive overall oral health 
assessment, what impact does this have on potential  “teachable moments” with 
our patients?  Finally, if primary care dental providers, who have the depth and 
breadth of knowledge to identify which oral lesions are potentially worrisome and 
which are not, don’t provide this crucial service, who will? 
I leave the reader with the following insightful comments from Dr. Robert A. 
Faiella, president of the American Dental Association (ADA), and Dr. Paul D. 
Freedman, president of the American Academy of Oral and Maxillofacial 
Pathology (AAOMP), written in response to similarly worded recommendations 
published in Consumers Reports magazine11: “Oral cancer screenings are not 
intended to be a stand-alone or separate procedure …oral cancer screenings 
should be part of the complete dental examination that is to be performed on all 
patients. During these complete exams your dentist is checking for ALL oral 
diseases and pathologic conditions. These non-invasive visual and tactile 
examinations, (which are generally included with no additional fee for the cancer 
screening component) can result in earlier diagnosis of oral cancer specifically 
but also a multitude of other oral diseases in general. The ADA and AAOMP will 
continue to support and encourage scientific investigations regarding detection of 
oral cancer, with the firm belief that one missed oral cancer is one too many12.“ 
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